Polaris Group

6550 · TWSE · Taiwan

Public Market Listing

6550TWSE

TWSE primary exchange listing

Live quotes, historical charts, and market capitalization for Polaris Group are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
Arginine-depleting pegylated arginine deiminaseProtein / enzyme therapeutic
Acute Myeloid LeukemiaHepatocellular Carcinoma

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
PegargiminasePhase 2Glioblastoma Multiforme (GBM)
Est. primary completion 2027-02-28 · NCT04587830 · CT.gov ↗
What to watch
December 2027 (1)
PegargiminasePhase 2Nonalcoholic Steatohepatitis (NASH)
Est. primary completion 2027-12-31 · NCT05842512 · CT.gov ↗
What to watch
2028 (1)
September 2028 (1)
PegargiminasePhase 3Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
Est. primary completion 2028-09 · NCT05317819 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

25 May 2026WithdrawalPegargiminasePolaris withdraws its US BLA for pegargiminase (ADI-PEG 20) in malignant pleural mesothelioma
US, FDA · Polaris Group · Source ↗
18 August 2025Filing acceptedPegargiminasePegargiminase (ADI-PEG 20) BLA entered FDA substantive review
US, FDA · Source ↗
9 June 2025Filing submittedPegargiminasePegargiminase BLA submission completed for MPM
US, FDA · Source ↗

Financial reports

No financial reports recorded.